Trait Name |
Trait Full Name |
Panel |
Author |
Year |
Cases* |
Controls |
TAG Set Threshold |
CSEA p (chi2) |
ADHD | Attention Deficit Hyperactivity Disorder | ETC | Demontis | 2017 | 19099 | 34194 | 1.00e-4 | 1.69e-2 |
Aggression | Aggression | MTC | Pappa | 2015 | NA | 15668 | 1.00e-2 | 4.09e-3 |
Cognitive Performance | Cognitive Performance | MTC | Rietveld | 2014 | NA | 106736 | 5.00e-2 | 1.84e-2 |
CAD | Coronary Artery Disease | MTC | C4D | 2011 | 64762 | 22233 | 5.00e-2 | 4.55e-2 |
CD | Crohn's disease | MTC | Franke | 2010 | 6333 | 15056 | 1.00e-2 | 2.23e-3 |
CD | Crohn's disease | MTC | Franke | 2010 | 6333 | 15056 | 1.00e-3 | 1.49e-2 |
CD | Crohn's disease | MTC | Franke | 2010 | 6333 | 15056 | 1.00e-4 | 4.73e-2 |
CD | Crohn's disease | MTC | Lee | 2017 | 1762 | 972 | 1.00e-4 | 7.43e-3 |
CD | Crohn's disease | MTC | Lee | 2017 | 1762 | 972 | 1.00e-5 | 5.94e-3 |
Depressive Symptoms | Depressive Symptoms | ETC | Okbay | 2016 | 122210 | 58835 | 5.00e-2 | 4.83e-3 |
Intelligence | Intelligence | MTC | Sniekers | 2017 | NA | 78308 | 5.00e-2 | 2.99e-2 |
Parkinsons | Parkinson's Disease | MTC | Pankratz | 2012 | 4238 | 4239 | 5.00e-2 | 2.46e-2 |
Self Rated Health | Self Rated Health | MTC | Harris | 2016 | NA | 111749 | 5.00e-2 | 2.00e-2 |
Self Rated Health | Self Rated Health | MTC | Harris | 2016 | NA | 111749 | 1.00e-2 | 8.23e-4 |
Self Rated Health | Self Rated Health | MTC | Harris | 2016 | NA | 111749 | 1.00e-3 | 7.81e-3 |
Self Rated Health | Self Rated Health | MTC | Harris | 2016 | NA | 111749 | 1.00e-4 | 4.31e-2 |
Self Rated Health | Self Rated Health | MTC | Harris | 2016 | NA | 111749 | 1.00e-5 | 2.31e-2 |
Albuminuria | Microalbuminuria | MTC | Boger | 2011 | NA | 31580 | 5.00e-2 | 1.01e-2 |
Albuminuria | Microalbuminuria | MTC | Boger | 2011 | NA | 31580 | 1.00e-2 | 3.13e-2 |
Aortic Valve Calcification | Mitral Annular Calcification | MTC | Thanassoulis | 2013 | NA | 3795 | 5.00e-2 | 4.24e-2 |
Blood Cells | Lymphocyte Counts | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 3.17e-2 |
Blood Cells | Lymphocyte Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-3 | 1.91e-2 |
Blood Cells | Platelet Counts | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 3.45e-2 |
Blood Cells | Platelet Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 2.46e-2 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-3 | 4.31e-2 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-4 | 2.97e-3 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-5 | 1.37e-3 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-4 | 8.03e-3 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-5 | 7.00e-3 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Inactive European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-3 | 4.89e-2 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 5.86e-3 |
Bone Mineral Density | Lumbar Spine Bone Mineral Density | MTC | Zheng | 2015 | NA | 23699 | 5.00e-2 | 3.94e-2 |
Ectopic Fat Traits | Pericardial Adipose Tissue Volume Adjusted For Height Weight All | MTC | Chu | 2017 | NA | 7324 | 1.00e-3 | 1.82e-2 |
Ectopic Fat Traits | Subcutaneous Adipose Tissue Attenuation Women | MTC | Chu | 2017 | NA | 5699 | 1.00e-3 | 3.58e-2 |
Ectopic Fat Traits | Visceral Adipose Tissue Attenutation Men | MTC | Chu | 2017 | NA | 5749 | 1.00e-3 | 3.76e-2 |
Educational Attainment | Education Years Women | MTC | Okbay | 2016 | 0 | 293723 men and women | 1.00e-4 | 2.83e-2 |
Facial Shape | Mod1 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 5.68e-3 |
Facial Shape | Mod1 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 1.73e-2 |
Facial Shape | Mod12 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 2.21e-2 |
Facial Shape | Mod17 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 1.08e-2 |
Facial Shape | Mod25 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 3.35e-2 |
Facial Shape | Mod25 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 4.36e-2 |
Facial Shape | Mod26 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 3.32e-2 |
Facial Shape | Mod3 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 4.56e-2 |
Facial Shape | Mod34 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 4.35e-2 |
Facial Shape | Mod50 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 4.51e-2 |
Facial Shape | Mod51 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 4.89e-2 |
Facial Shape | Mod6 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 1.88e-3 |
Facial Shape | Mod8 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 1.56e-2 |
Inflammatory Bowel Disease European | Crohn's disease | ETC | Liu | 2015 | 5956 | 14927 | 5.00e-2 | 3.99e-2 |
Inflammatory Bowel Disease European | Crohn's disease | ETC | Liu | 2015 | 5956 | 14927 | 1.00e-2 | 3.46e-3 |
Inflammatory Bowel Disease European | Crohn's disease | ETC | Liu | 2015 | 5956 | 14927 | 1.00e-3 | 1.53e-2 |
Inflammatory Bowel Disease European | Crohn's disease | ETC | Liu | 2015 | 5956 | 14927 | 1.00e-4 | 3.96e-2 |
Inflammatory Bowel Disease European | Inflammatory Bowel Disease | ETC | Liu | 2015 | 12882 | 21770 | 5.00e-2 | 3.46e-2 |
Inflammatory Bowel Disease European | Ulcerative Colitis | ETC | Liu | 2015 | 6968 | 20464 | 1.00e-4 | 3.74e-2 |
Insulin Sensitivity Index | Model 2 | MTC | Walford | 2016 | NA | 16753 | 1.00e-2 | 6.19e-3 |
Insulin Sensitivity Index | Model 3 | MTC | Walford | 2016 | NA | 16753 | 5.00e-2 | 4.81e-2 |
Loneliness | Loneliness | MTC | Gao | 2017 | NA | 6924 | 1.00e-2 | 4.78e-2 |
Reproductive Behavior | Number Children Ever Born Male | MTC | Barban | 2016 | NA | 103909 | 5.00e-2 | 2.95e-2 |
Sleep Duration | Oversleeper | MTC | Jones | 2016 | NA | 91306 | 5.00e-2 | 2.04e-3 |
Sleep Duration | Oversleeper | MTC | Jones | 2016 | NA | 91306 | 1.00e-2 | 3.67e-2 |
Sleep Duration | Undersleeper | MTC | Jones | 2016 | NA | 110188 | 1.00e-2 | 2.52e-3 |
Sleep Duration | Average Sleep Duration | MTC | Jones | 2016 | NA | 127573 | 1.00e-5 | 2.21e-2 |
Smoking | Cigarettes Per Day | ETC | Furberg | 2010 | NA | 38181 | 1.00e-3 | 1.38e-2 |
Social Deprivation | Townsend Score | MTC | Hill | 2016 | NA | 96900 | 5.00e-2 | 1.66e-2 |
Social Deprivation | Townsend Score | MTC | Hill | 2016 | NA | 96900 | 1.00e-2 | 2.82e-2 |
Statin Efficacy | Delta HDL | MTC | Barber | 2010 | NA | 3928 | 1.00e-2 | 4.72e-2 |
Statin Efficacy | Delta HDL | MTC | Barber | 2010 | NA | 3928 | 1.00e-3 | 2.14e-2 |
MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 1.00e-2 | 2.51e-2 |
CEL | Celiac Disease | ETC | Trynka | 2011 | 12041 | 12228 | 5.00e-2 | 1.97e-2 |
CEL | Celiac Disease | ETC | Trynka | 2011 | 12041 | 12228 | 1.00e-2 | 4.53e-2 |
CEL | Celiac Disease | ETC | Trynka | 2011 | 12041 | 12228 | 1.00e-5 | 2.62e-2 |
Facial attractiveness | Facial attractiveness of males, male raters | ETC | Hu | 2019 | NA | 1792 | 5.00e-2 | 4.40e-2 |
Facial attractiveness | Facial attractiveness of males, female raters | ETC | Hu | 2019 | NA | 1792 | 5.00e-2 | 1.39e-2 |
Neuroticism | Worry-vulnerability-special-factor-of-neuroticism | ETC | Hill | 2019 | NA | 270059 | 1.00e-5 | 4.73e-2 |
Neuroticism | Anxiety-tension-special-factor-of-neuroticism | ETC | Hill | 2019 | NA | 270059 | 1.00e-5 | 4.73e-2 |
Sleep | Sleep duration, long sleep | ETC | Dashti | 2019 | 34184 | 305742 | 1.00e-2 | 2.38e-3 |
Sleep | Sleep duration, long sleep | ETC | Dashti | 2019 | 34184 | 305742 | 1.00e-3 | 3.26e-2 |
Obesity | Obese children vs thin adults | ETC | McKay | 2019 | 1471 | 1456 | 1.00e-2 | 2.84e-2 |
Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 1.00e-2 | 3.39e-2 |
Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 1.00e-4 | 4.15e-2 |
Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 1.00e-5 | 4.00e-2 |
Erectile dysfunction | Erectile dysfunction | ETC | Bovijn | 2018 | 6175 | 217630 | 1.00e-3 | 1.26e-3 |
IHPS | Infantile hypertrophic pyloric stenosis | ETC | Fadista | 2018 | NA | 4438 | 1.00e-2 | 3.96e-2 |
Medication use | Medication use (antidepressants) | ETC | Wu Y | 2019 | 33,757 | 270,405 | 5.00e-2 | 3.86e-2 |
Medication use | Medication use (antidepressants) | ETC | Wu Y | 2019 | 33,757 | 270,405 | 1.00e-3 | 1.31e-3 |
Medication use | Medication use (antidepressants) | ETC | Wu Y | 2019 | 33,757 | 270,405 | 1.00e-4 | 4.61e-2 |
Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 1.00e-4 | 3.25e-2 |
Medication use | Medication use (antihistamines for systemic use) | ETC | Wu Y | 2019 | 13,984 | 137,652 | 1.00e-2 | 6.62e-3 |
Periodontal disease | Periodontal disease related phenotype (PCT2) | ETC | Offenbacher S | 2016 | NA | 975 | 5.00e-2 | 3.90e-2 |
Nonalcoholic Liver disease | Non-alcoholic fatty liver disease activity score | ETC | Namjou B | 2019 | NA | 235 | 1.00e-2 | 4.00e-2 |
Autistic traits score | Autistic traits score (Social and Communication Disorders Checklist) | ETC | Massrali A | 2019 | NA | 5,628 | 1.00e-2 | 1.60e-2 |
Autistic traits score | Autistic traits score (Social and Communication Disorders Checklist) | ETC | Massrali A | 2019 | NA | 5,628 | 1.00e-3 | 9.38e-3 |
same-sex sexual behaviour | same-sex sexual behaviour Male | ETC | Ganna A | 2019 | NA | 188,825 | 1.00e-3 | 3.11e-2 |
Asthma | Asthma (childhood onset) | ETC | Zhu Z | 2019 | 9,676 | 347,481 | 1.00e-2 | 4.99e-2 |
Cytokine network | Cytokine network levels (multivariate analysis) | ETC | Nath AP | 2019 | NA | 9,263 | 1.00e-3 | 2.72e-2 |
Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (MPO-ANCA positive) | ETC | Lyons PA | 2019 | 159 | 6,688 | 5.00e-2 | 3.75e-3 |
Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (MPO-ANCA positive) | ETC | Lyons PA | 2019 | 159 | 6,688 | 1.00e-2 | 2.39e-2 |
Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis | ETC | Lyons PA | 2019 | 534 | 6,688 | 5.00e-2 | 2.36e-2 |
BMI by age | BMI at 8 years old | ETC | Helgeland O | 2019 | NA | 3,862 | 1.00e-2 | 1.40e-2 |
Central corneal thickness | Central corneal thickness | ETC | Bonnemaijer PWM | 2019 | NA | 16,204 | 1.00e-5 | 3.57e-2 |
Temporale asymmetry | Planum temporale asymmetry index | ETC | Carrion-Castillo A | 2020 | NA | 18,049 | 5.00e-2 | 4.95e-2 |
Heart failure | Heart failure | ETC | Shah S | 2020 | 47,309 | 930,014 | 5.00e-2 | 1.89e-2 |
IL 6 | Interleukin-6 receptor subunit alpha levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 1.00e-2 |
CCL24 | CCL24 levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 1.19e-2 |
CCL24 | CCL24 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 3.04e-2 |
CCL24 | CCL24 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 1.64e-2 |
CCL24 | CCL24 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 2.83e-2 |
CCL24 | CCL24 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 2.58e-2 |
MHC class I | MHC class I polypeptide-related sequence A levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 4.90e-3 |
MHC class I | MHC class I polypeptide-related sequence A levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 2.59e-2 |
MHC class I | MHC class I polypeptide-related sequence A levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 2.82e-2 |
Kallikrein11 | kallikrein-11 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 3.05e-2 |
* If the number of cases is 0/NA, it means the phenotype is a continuous data type and the number of controls is the total number of samples.